1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?

Scope

Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, interferon-sparing hepatitis C therapies, with this success expected to be centred on its combination sofosbuvir plus ledipasvir franchise. Final Phase III data for this combination therapy are expected to emerge in early 2014, with potential approval secured towards the end of next year.

However, impressive Phase III data released earlier this week from the first of six late-stage studies for AbbVie’s ‘3D’ regimen - which puts the company on a similar regulatory timescale to Gilead – suggest that the US biotech will not be competing completely on its own terms. Similarly, analysts have recently pointed out that Merck & Co. could also emerge as a viable competitor in the genotype 1 space.

A number of analysts noted that data from the SAPPHIRE study confirm AbbVie’s competitive position among the first generation of interferon-free therapies for genotype 1 patients, given the efficacy and safety of its regimen.

A consensus appears to be emerging that AbbVie could secure a 10 percent to 15 percent share of the market, despite its regimen being more complex to dose – a multi-tablet (six) therapy dosed twice-daily (versus Gilead’s once-daily fixed-dose combination) – and including ritonavir – which can increase drug-drug interactions.

Analysts at Goldman Sachs argue that Merck’s Victrelis previously achieved a 20 percent to 30 percent share of the hepatitis C market, despite being a "worse regimen" relative to Vertex’s Incivek than AbbVie’s ‘3D’ regimen is to sofosbuvir + ledipasvir. Possibly reflecting a pharma to biotech disconnect, they also point to 2015 forecast hepatitis C sales for Gilead being 10 times those currently anticipated for AbbVie.

Reasons to Buy This Report

To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious disease specialists based in the US and EU5. Specifically the poll will ask them:

• What percentage of diagnosed but untreated genotype 1 hepatitis C patients they expect to warehouse until interferon-free therapies are made available – anticipated in late 2014/early 2015?
• Assuming cure rates are comparable, to what percentage of genotype 1 patients they would prescribe an interferon-sparing, once-daily, single-tablet therapy rather than an interferon-sparing multi-tablet therapy dosed five-times daily?
• What their level of concern is regarding ritonavir-boosting in future interferon-sparing regimens?
• Whether prescribing Gilead’s sofosbuvir during 2014 will positively influence their subsequent prescribing habits for an interferon-free sofosbuvir-based regimen in genotype 1 patients?
• To what percentage of genotype 1 patients they expect to prescribe Gilead’s sofosbuvir + ledipasvir fixed-dose combination?





Table Of Contents

Physician Views: Entering the post-interferon era - will Gilead Sciences dominate hepatitis C?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Infectious Disease Statistics and Anti-Infective Market in India - Forecast

  • January 2017
    7 pages
  • Infectious Dise...  

    Anti-Infective  

  • India  

View report >

Therapy Market in the US

  • January 2017
    7 pages
  • Therapy  

    Therapy  

  • United States  

View report >

Related Market Segments :

Therapy
Hepatitis C
Interferon

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.